See You At ITEXPO & The #TechSuperShow | February 11-14, 2020 | Fort Lauderdale, Florida REGISTER TODAY.
SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets
[January 14, 2020]

Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets


NEW YORK, Jan. 14, 2020 /PRNewswire/ --  Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.

Insilico Collaborates with Pfizer on Novel Data and Artificial Intelligence System for Target Discovery.

"Insilico is advancing its latest target identification systems utilizing machine learning, generative biology methods, and synthetic data generation pipelines, and we are pleased to be collaborating with Pfizer on its target identification efforts," said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine.

"We look forward to working with Insilico as Pfizer continues to explore new technologies that may be able to help us identify targets and biomarkers that could assist in our discovery programs, and potentially lead to breakthrough therapeutics for patients with unmet medical needs, said Morten Sogaard, Vice President, Target Sciences, Pfizer.



In September 2019, Insilico Medicine announced a $37 million round led by prominent biotechnology and AI investors.

About Insilico Medicine
Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine published some of the results in Nature Biotechnology, and secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 70 peer-reviewed papers, applied for over 20 patents, and received multiple industry awards.


Website http://insilico.com/

Media Contact
For further information, images or interviews, please contact:
ai@insilico.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/insilico-enters-into-research-collaboration-with-pfizer-inc-to-explore-novel-data-and-artificial-intelligence-system-for-potential-therapeutic-targets-300986562.html

SOURCE Insilico Medicine


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA
Ph: +1-203-852-6800, 800-243-6002

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2020 Technology Marketing Corporation. All rights reserved | Privacy Policy